Stockreport

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF Deucrictibant substantially resolved symptoms of an HAE attack in 78.6% participants within 24 hoursHigh treatment satisfaction of deucrictibant driven by favorable effe [Read more]